AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03756064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet: 400mg orally daily
Study NCT04322916 — intervention group
Intervention type: DEVICE
Intervention: RM Pressfit vitamys
Description: Implantation of a RM Pressfit vitamys hip cup
Study NCT04019249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight Coaching
Description: Healthy Weight Coaching is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
Study NCT00335374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pardoprunox
Description: 12 -42 mg
Study NCT02388113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: accumulated exercise
Study NCT02388113 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional exercise
Study NCT02568878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate
Study NCT03618836 — intervention group
Intervention type: OTHER
Intervention: Microbiological and biological patterns on vaginal samples
Description: To compare the microbiological and biological patterns between groups
Study NCT03598725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIII
Description: Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day
Study NCT03598725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 2mg/kg every day for 4 weeks then typering in 3 months
Study NCT03598725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/Square meter for consecutive 4 months
Study NCT03803553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: FOLFIRI cycle will be two weeks (14 days) long, with FOLFIRI administered on Days 1-3. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of FOLFIRI chemotherapy.
Study NCT03803553 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVE SURVEILLANCE
Description: Will be followed with observation and monitoring with imaging, tumor markers, and ctDNA collections
Study NCT03803553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Protocol
Description: Nivolumab cycle will be four weeks (28 days) long, with Nivolumab administered on day 1. Participants will receive up to 12 four-week cycles (for a total of 48 weeks) of Nivolumab treatment.
Study NCT03803553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib/Binimetinib/Cetuximab Protocol
Description: Encorafenib/Binimetinib will be taken orally every day and Cetuximab will be administered intravenously on day 1 of each cycle. Cycles are 14 days long. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of Encorafenib/Binimetinib/Cetuximab.
Study NCT03803553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab + Pertuzumab
Description: Trastuzumab (Herceptin) is received by intravenous administration and Pertuzumab is received intravenously by infusion on Day 1 of each cycle. Cycles are 21 days long. Participants will receive up to 8 cycles of Trastuzumab and Pertuzumab.
Study NCT03280108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix Multifocal IOL
Description: AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision
Study NCT03280108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof Monofocal IOL
Description: AcrySof Monofocal IOL Model SN60AT for single vision
Study NCT01512914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 30 mg
Description: preoperative instillation of saline 20 ml, nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and nebulization of saline 3 ml after surgery
Study NCT01512914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 30 mg
Description: preoperative instillation of saline 20 ml, preoperative nebulization of saline 3 ml and nebulization of ropivacaine 1% 3 ml (30 mg) after surgery
Study NCT01512914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 100 mg
Description: preoperative instillation of ropivacaine 0,5% 20 ml (100 mg) and nebulization of saline 3 ml before and after surgery
Study NCT01512914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: preoperative instillation of saline 20 ml and nebulization of saline before and after surgery
Study NCT04006236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Infant Formula
Description: Feed Ad Libitum
Study NCT04006236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Infant Formula
Description: Feed Ad Libitum
Study NCT02801409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia alone
Description: General anesthesia is performed during surgery; patient-controlled intravenous analgesia is provided after surgery.
Study NCT02801409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined epidural-general anesthesia
Description: Combined epidural-general anesthesia is performed during surgery; patient-controlled epidural analgesia is provided after surgery.
Study NCT03800485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT
Description: A training protocol of the inspiratory muscles that goes from the 15% of the maximal inspiratory muscle preassure until the 60% of the maximal inspiratory muscle preassure during 8 weeks
Study NCT03800485 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: IMT
Description: A training protocol of the inspiratory muscles that goes from the 15% of the maximal inspiratory muscle preassure until the 60% of the maximal inspiratory muscle preassure during 8 weeks
Study NCT00604513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready. Set. ACTION! Protocol
Description: The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a check-in about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun \& Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception.
Study NCT00604513 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
Study NCT04007146 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcutaneous oxymetry measurement
Description: Transcutaneous oxymetry measurement with transient hyperoxia period (2 periods of 30seconds at 60% of oxygen)
Study NCT01187407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Study NCT01187407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01187407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01187407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
Study NCT01187407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
Study NCT00874497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tetomilast
Description: Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years.
Study NCT00874497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for 104 weeks (2 years)
Study NCT03269695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06687234
Description: SC QW
Study NCT03269695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC QW
Study NCT01344499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide
Description: standard pneumoperitoneum with 100% CO2
Study NCT01344499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carbon dioxide
Description: standard pneumoperitoneum with 100% CO2
Study NCT01344499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: full conditioning
Description: Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
Study NCT01344499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: full conditioning
Description: Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
Study NCT01344499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adept
Description: instillation of 1 liter of fluid at the end of laparoscopy
Study NCT01344499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer Lactate
Description: instillation of 1 liter of fluid at the end of laparoscopy
Study NCT04202016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision Surgery
Description: After a surgical cut using #15 surgical blade 2-3 mm distal to the canine a pizocision using piezo-surgery device is made.
Study NCT01728688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBSC transplantation
Description: PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery
Study NCT01728688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: Participants will receive conventional treatment and antiviral treatment.
Study NCT00857233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 20 mg oral tablets once daily
Study NCT02276209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 4 mg once daily
Study NCT02276209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasotraline
Description: Dasotraline 6 mg once daily
Study NCT02276209 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study NCT02010398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-Training healthy subjects
Description: The phase of intervention will consist of a 6-week cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
Study NCT02010398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-Training multiple sclerosis
Description: The phase of intervention will consist of a 6-week cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
Study NCT02010398 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-training multiple sclerosis
Description: The phase of intervention will consist of a 6-week standard strength training of the more-impaired limb employing an isokinetic contraction regimen performed at maximal intensity.
Study NCT03458923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium 0.1 ml containing 500µg
Description: 15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months
Study NCT03458923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.5 mg Solution for Injection
Description: 15 eyes will receive intravitreal 0.5 mg of Ranibizumab monthly for three months
Study NCT02418741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck flexion
Description: Patient's neck was flexed using a 4 cm or 8 cm height of pillow
Study NCT03447652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Band Ankle Rehabilitation
Description: Resistance Band - uses a tension band to provide resistance during ankle motion
Study NCT03447652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomechanical Ankle Platform System Rehabilitation
Description: Biomechanical Ankle Platform System Board Group - uses different levels of half spheres to increase the amount of motion allowed at the ankle.
Study NCT01603771 — intervention group
Intervention type: OTHER
Intervention: Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)
Description: All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
Study NCT02625753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine
Description: Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
Study NCT02625753 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
Study NCT02625753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
Study NCT04232878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-936
Description: CVL-936
Study NCT04232878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-936
Study NCT02222961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIR 561 CL
Study NCT02222961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04389346 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periapical surgery using autologous platelet aggregate
Description: PRF will be placed over the denuded root surface, following apicoectomy and before flap repositioning
Study NCT04389346 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periapical surgery without autologous platelet aggregate
Description: Flap will be repositioned following apicoectomy directly without placing any platelet aggregate
Study NCT02028468 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemiarthroplasty
Study NCT03447652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Rehabilitation
Description: Combination Group - includes both the resistance band and Biomechanical Ankle Platform System programs.
Study NCT01366794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrients
Description: Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
Study NCT01818427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infusion of 2 units of plasma
Description: infusion of 2 units of plasma
Study NCT01658956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF administration on days 8 and 12 after chemotherapy
Study NCT00488228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-regulation
Description: The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
Study NCT02622711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DI
Description: Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
Study NCT02622711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAI
Description: Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
Study NCT02622711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PADI
Description: Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
Study NCT02622711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LII
Description: Participants will be considered as control group. They will receive a general healthy counselling providing materials and guidelines available for the general public.
Study NCT04124783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Bolero
Description: A vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
Study NCT00363649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-K562 cell vaccine
Description: Given by injection
Study NCT00363649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon alfa
Description: Given by injection
Study NCT00363649 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given by injection
Study NCT00002597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.
Study NCT00002597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: 3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
Study NCT00002597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupron
Description: 7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
Study NCT00002597 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 46.8 Gy (1.8 Gy/day four to five times a week \[26 fx\]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.
Study NCT00002597 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: 46.8 Gy (1.8 Gy/day four to five times a week \[26 fx\]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.
Study NCT03530488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline
Study NCT03530488 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Office hystroscopy
Description: A rigid 3.5 mm hystroscope with an optic of 30 degrees was used. Normal saline solution was used as distension media, with 120 mmHg intrauterine pressure, Vaginoscopic approach, nocervical tenaculum or dilators used.
Study NCT03530488 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Office hystroscopy
Description: A rigid 3.5 mm hystroscope with an optic of 30 degrees was used. Normal saline solution was used as distension media, with 120 mmHg intrauterine pressure, Vaginoscopic approach, nocervical tenaculum or dilators used.
Study NCT02940210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mediclore® (adhesion barrier)
Study NCT02725398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buscopan
Description: Buscopan is administered by endoscopic nurse in the Buscopan group,and then recording the outcome measures.
Study NCT02725398 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: Scopolamine is administered by endoscopic nurse in the Scopolamine group,and then recording the outcome measures.
Study NCT02725398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: Physiological saline is administered by endoscopic nurse in the physiological saline group,and then recording the outcome measures.
Study NCT00946205 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic posterior rectopexy
Description: The rectum is mobilised down to the os coccygeus, then it is elevated cephalic and sutured with a multifilament suture to the presacral fascia just below the sacral promontory. The lateral stalks should be left intact.